April 25 (Reuters) - AstraZeneca reported quarterly revenue and profit above market estimates on Thursday, buoyed by resilient demand for its oncology and rare blood disorder drugs.
The London-listed drugmaker reported core earnings per share of $2.06 on total revenue of $12.68 billion for the first quarter.
Analysts were expecting a core profit of $1.92 per share on revenue of $11.84 billion, according to a company-compiled consensus.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments